Repare Therapeutics (RPTX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

RPTX Repare Therapeutics

Watchlist

3.320
+0.170+5.40%

Close Nov 27 16:00 ET

141.14MMarket Cap-1668P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
BenzingaNov 27 16:05 ET
Express News | Repare Therapeutics Announces Agreement With the US National Cancer Institute to Advance the Development of Camonsertib
ReutersNov 12 07:05 ET
Morgan Stanley Maintains Repare Therapeutics(RPTX.US) With Hold Rating, Maintains Target Price $8
Moomoo NewsNov 11 08:31 ET · Ratings
Morgan Stanley Sticks to Their Hold Rating for Repare Therapeutics (RPTX)
TipRanksNov 11 08:21 ET · Ratings
Stifel Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $9
Moomoo NewsNov 8 10:31 ET · Ratings
Repare Therapeutics: Strong Financial Health and Promising Data Catalysts Justify Buy Rating With $10 Price Target
TipRanksNov 8 10:25 ET · Ratings

Comments

Jaguar8

Nov 12 06:05

NEWS

$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics has announced a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) to advance camonsertib, their oral ATR inhibitor for cancer treatment. The drug has shown significant anti-tumor activity in preclinical and clinical studies, particularly ...

Trytosaveabit

Oct 23 05:10

Update

$Repare Therapeutics (RPTX.US)$ Reuters· 4 mins ago
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results From the Phase 1 Mythic Clinical Trial

Trytosaveabit

Oct 14 06:11

Update

$Repare Therapeutics (RPTX.US)$ Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
5 MINUTES AGO, 7:05 AM EDT
VIA BUSINESSWIRE

Stock_Drift

Sep 30 15:16

After Hours Ticks, 4:14pm, EST.

$Mill City Ventures III (MCVT.US)$ $Jowell Global (JWEL.US)$ $NCI (01336.HK)$ $Onconetix (ONCO.US)$ $YXT.COM Group Holding (YXT.US)$ $Cognition Therapeutics (CGTX.US)$ $Ambow Education (AMBO.US)$ $Matinas BioPharma (MTNB.US)$ $TCTM Kids IT Education (TCTM.US)$ $N2OFF (NITO.US)$ $Repare Therapeutics (RPTX.US)$ $ZK International (ZKIN.US)$
📊⚡️📊

Jaguar8

Sep 30 15:12

NEWS

$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Repare Therapeutics (Nasdaq: RPTX) presented Phase 1 data at the ASTRO Annual Meeting, showcasing the potential of camonsertib, an oral ATR inhibitor, combined with palliative radiation for treating metastatic tumors with ATM mutations.
The study enrolled 17 patients, 12 with pathogenic ATM mutations and 5 with va...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

RPTX Repare Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target